https://medicalxpress.com/news/2019-09-melanoma-cancer.html
ITV Tyne Tees presenter, Pam Royle, is one of the first to try a new test developed by Newcastle University which predicts whether her skin cancer is likely to return.
The test which reliably predicts that a melanoma is unlikely to spread or return has been developed by scientists at Newcastle University.
The pioneering test is expected to be available within 2 years, offering reassurance for patients with melanoma, the most deadly form of skin cancer.
Called AMBLor, the prognostic test for the earliest stages of melanoma is able to better identify a patient's true risk of disease progression. It provides all those diagnosed with stage 1 melanoma with more accurate information about the risk of the disease spreading. This is up to 70 percent of new patients.
The team tested 400 archived biopsies from patients who had a stage 1 melanoma diagnosis and showed that the test could predict long term prognosis of the disease and in the future could help clinicians develop personalized treatment plans for patients.
ITV Tyne Tees presenter, Pam Royle, is one of the first to try a new test developed by Newcastle University which predicts whether her skin cancer is likely to return.
The test which reliably predicts that a melanoma is unlikely to spread or return has been developed by scientists at Newcastle University.
The pioneering test is expected to be available within 2 years, offering reassurance for patients with melanoma, the most deadly form of skin cancer.
Called AMBLor, the prognostic test for the earliest stages of melanoma is able to better identify a patient's true risk of disease progression. It provides all those diagnosed with stage 1 melanoma with more accurate information about the risk of the disease spreading. This is up to 70 percent of new patients.
The team tested 400 archived biopsies from patients who had a stage 1 melanoma diagnosis and showed that the test could predict long term prognosis of the disease and in the future could help clinicians develop personalized treatment plans for patients.